Whilst Richard had an early career as a successful artist based in France he is now known for his pioneering work in material science and bio-photonic medical research.
Over the last few years he has focused on opportunities in the emerging biophotonic therapeutics sector using the effects of light on the body to develop unique and novel approaches to the treatment of macular eye disease. The launch of the Noctura 400 Sleep Mask, a non-invasive and ground breaking treatment for diabetic eye disease, has changed the paradigm of how this sight threatening disease is managed, and for the first time offers a cost effective option for both late stage treatment and early stage prevention of this common but very serious complication of diabetes.
He is credited for many world's first applications using inorganic and organic light emitting materials. He is a regular keynote speaker internationally and sits on a number of industrial and government advisory boards. Richard and his company have won many international and national awards for innovation, research and business.
Given Richard's unconventional/remarkable background he has a thorough understanding of the creative process, and takes a unique and entrepreneurial view on the development of markets for innovative research.
PolyPhotonix is a bio-photonic business based in the UK that has developed a home-based, non-invasive, monitored treatment for one of the principal causes of blindness in the western world, Diabetic Retinopathy and Diabetic Macular Oedema. The Noctura 400 Sleep Mask, offers a novel and innovative treatment for Diabetic patients with serious sight complications, and it will significantly change the patient experience and related costs when compared with current treatments. Noctura 400 is the first product launched by the company from a portfolio of bio-photonic medical devices that are under development by PolyPhotonix
